Total amount: € 0,00
HOW TO ORDER
A Journal on Angiology
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
International Angiology 2011 June;30(3):272-7
Correlation between improvement in functional signs and plethysmographic parameters during venoactive treatment (Cyclo 3 Fort)
Allaert F. A. 1, Hugue C. 2, Cazaubon M. 3, Renaudin J. M. 2, Clavel T. 4, Escourrou P. 5 ✉
1 Medical Evaluation, ESC CHU, Dijon, France;
2 Angiologists, Sceaux, France;
3 Angiology, American Hospital, Neuilly, France;
4 Pierre Fabre Médicament, Castres, France;
5 Functional Investigations, Hôpital Béclère, Clamart, France
AIM: The aim of this study was to compare the change in functional signs of venous insufficiency and venous refilling time measured by mercury strain-gauge plethysmography under the effects of the combination of Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid (Cyclo 3 Fort).
METHODS: An open-label clinical trial conducted in 65 women presenting with CEAP class C2s and C3s assessment criteria. At D0 and D28, functional signs were measured on a visual analog scale (VAS), venous refilling time by mercury strain-gauge plethysmography and venous reflux by echo-Doppler method.
RESULTS: Under treatment, venous refilling time increased from 11.7±4 s to 13.8±4.4 s with Δ of 26% (P<0.0001) and the percentage of patients showing improvement of functional symptoms ≥30% was significantly correlated (P=0.04) with the percentage of patients presenting an improvement in venous refilling time ≥10%.
CONCLUSION: Improvement in subjective functional signs under treatment with Cyclo 3 Fort was correlated with objective plethysmographic parameter improvement. There-fore, this study contributes to objectively document the benefit of prescribing this venoactive drug to active women with CEAP class C2s to C3s